Fideuram Intesa Sanpaolo Private Banking S.P.A. Acquires New Position in Royalty Pharma PLC $RPRX

Fideuram Intesa Sanpaolo Private Banking S.P.A. acquired a new stake in Royalty Pharma PLC (NASDAQ:RPRX) during the fourth quarter, Holdings Channel.com reports. The institutional investor acquired 127,419 shares of the biopharmaceutical company’s stock, valued at approximately $4,923,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Smartleaf Asset Management LLC raised its stake in shares of Royalty Pharma by 868.1% during the 3rd quarter. Smartleaf Asset Management LLC now owns 881 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 790 shares in the last quarter. Private Trust Co. NA boosted its stake in shares of Royalty Pharma by 52.9% in the fourth quarter. Private Trust Co. NA now owns 832 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 288 shares in the last quarter. Larson Financial Group LLC grew its holdings in Royalty Pharma by 31.9% during the third quarter. Larson Financial Group LLC now owns 1,264 shares of the biopharmaceutical company’s stock worth $45,000 after acquiring an additional 306 shares during the period. Fifth Third Bancorp grew its holdings in Royalty Pharma by 16.9% during the third quarter. Fifth Third Bancorp now owns 2,499 shares of the biopharmaceutical company’s stock worth $88,000 after acquiring an additional 362 shares during the period. Finally, Caitong International Asset Management Co. Ltd purchased a new position in Royalty Pharma in the third quarter worth $100,000. Institutional investors and hedge funds own 54.35% of the company’s stock.

Royalty Pharma Stock Up 1.2%

RPRX opened at $53.06 on Thursday. The company has a debt-to-equity ratio of 0.86, a quick ratio of 2.66 and a current ratio of 2.66. The company has a market cap of $30.55 billion, a price-to-earnings ratio of 36.10, a PEG ratio of 1.44 and a beta of 0.40. Royalty Pharma PLC has a one year low of $32.15 and a one year high of $53.47. The business’s fifty day moving average is $48.72 and its two-hundred day moving average is $43.73.

Royalty Pharma (NASDAQ:RPRX) last announced its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported $1.30 earnings per share for the quarter, beating analysts’ consensus estimates of $1.22 by $0.08. Royalty Pharma had a return on equity of 29.25% and a net margin of 33.88%.The business had revenue of $631.00 million during the quarter, compared to analysts’ expectations of $881.69 million. Analysts anticipate that Royalty Pharma PLC will post 5.05 EPS for the current fiscal year.

Royalty Pharma Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th will be given a dividend of $0.235 per share. The ex-dividend date is Friday, May 15th. This represents a $0.94 dividend on an annualized basis and a yield of 1.8%. Royalty Pharma’s payout ratio is presently 63.95%.

Analyst Ratings Changes

Several brokerages have commented on RPRX. The Goldman Sachs Group restated a “buy” rating on shares of Royalty Pharma in a research report on Thursday, February 12th. Morgan Stanley increased their price target on shares of Royalty Pharma from $61.00 to $63.00 and gave the company an “overweight” rating in a report on Friday, April 10th. Citigroup raised their price objective on shares of Royalty Pharma from $50.00 to $66.00 and gave the company a “buy” rating in a research note on Thursday, May 7th. Weiss Ratings downgraded shares of Royalty Pharma from a “buy (b)” rating to a “buy (b-)” rating in a report on Friday, May 15th. Finally, TD Cowen restated a “buy” rating on shares of Royalty Pharma in a research report on Friday, February 27th. Seven research analysts have rated the stock with a Buy rating, According to data from MarketBeat, Royalty Pharma currently has an average rating of “Buy” and a consensus target price of $53.71.

Insider Buying and Selling at Royalty Pharma

In other news, Director Gregory Norden sold 3,045 shares of the stock in a transaction that occurred on Thursday, May 14th. The shares were sold at an average price of $53.00, for a total value of $161,385.00. Following the sale, the director directly owned 191,803 shares in the company, valued at $10,165,559. This represents a 1.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marshall Urist sold 13,684 shares of the firm’s stock in a transaction that occurred on Thursday, May 14th. The stock was sold at an average price of $53.06, for a total transaction of $726,073.04. Following the transaction, the executive vice president directly owned 31,881 shares of the company’s stock, valued at approximately $1,691,605.86. This trade represents a 30.03% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 155,893 shares of company stock valued at $7,512,360 over the last quarter. Corporate insiders own 18.84% of the company’s stock.

About Royalty Pharma

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.